Dr George Frodsham

Founder & CEO at Medisieve

Speaker

Dr George Frodsham is the CEO and founder of MediSieve, a London based biotech that has developed a platform technology that enables the specific removal of harmful substances from the bloodstream. George spun out MediSieve from University College London following his PhD in biochemical engineering. He has received business and entrepreneurship training from the London Business School, the Royal Academy of Engineering, and the Royal Society of Edinburgh. In 2019, George was awarded the "Innovator of the Year" award by the Biotechnology and Biological Sciences Research Council and named one of MIT Tech Review's "30 under 30".

MediSieve is an innovative BioTech company based in the White City Innovation District of West London. A spin-off from University College London, MediSieve has developed a technology called Magnetic Blood Filtration, a transformative platform that provides the ability to physically remove or isolate specific substances directly from the bloodstream of patients. The company has a pipeline of both internal and partnered assets targeting large underserved conditions and patient populations in areas including gene therapy, oncology, autoimmune diseases and inflammation. The company is currently focussed on depleting AAV neturalising antibodies (NAbs) to enable gene therapies to be used on patients with pre-existing NAbs, including redosing.